Logo image of TECX

TECTONIC THERAPEUTIC INC (TECX) Stock Fundamental Analysis

NASDAQ:TECX - Nasdaq - US8789721086 - Common Stock - Currency: USD

54.84  +29.12 (+113.22%)

After market: 54.01 -0.83 (-1.51%)

Fundamental Rating

2

Overall TECX gets a fundamental rating of 2 out of 10. We evaluated TECX against 572 industry peers in the Biotechnology industry. TECX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TECX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TECX has reported negative net income.
TECX had a negative operating cash flow in the past year.
In the past 5 years TECX reported 4 times negative net income.
TECX had a negative operating cash flow in each of the past 5 years.
TECX Yearly Net Income VS EBIT VS OCF VS FCFTECX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 -20M -40M -60M -80M -100M

1.2 Ratios

TECX's Return On Assets of -32.24% is fine compared to the rest of the industry. TECX outperforms 64.78% of its industry peers.
The Return On Equity of TECX (-36.18%) is better than 74.87% of its industry peers.
Industry RankSector Rank
ROA -32.24%
ROE -36.18%
ROIC N/A
ROA(3y)-49.43%
ROA(5y)N/A
ROE(3y)-65.98%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TECX Yearly ROA, ROE, ROICTECX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 -50 -100

1.3 Margins

TECX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TECX Yearly Profit, Operating, Gross MarginsTECX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

The number of shares outstanding for TECX has been increased compared to 1 year ago.
TECX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TECX Yearly Shares OutstandingTECX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 1M 2M 3M
TECX Yearly Total Debt VS Total AssetsTECX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 50M 100M 150M 200M

2.2 Solvency

TECX has an Altman-Z score of 11.25. This indicates that TECX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of TECX (11.25) is better than 87.43% of its industry peers.
TECX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
TECX has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.25
ROIC/WACCN/A
WACCN/A
TECX Yearly LT Debt VS Equity VS FCFTECX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 50M -50M 100M -100M 150M

2.3 Liquidity

A Current Ratio of 9.39 indicates that TECX has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 9.39, TECX is in the better half of the industry, outperforming 78.41% of the companies in the same industry.
A Quick Ratio of 9.39 indicates that TECX has no problem at all paying its short term obligations.
TECX has a better Quick ratio (9.39) than 78.76% of its industry peers.
Industry RankSector Rank
Current Ratio 9.39
Quick Ratio 9.39
TECX Yearly Current Assets VS Current LiabilitesTECX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for TECX have decreased strongly by -399.49% in the last year.
EPS 1Y (TTM)-399.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-172.73%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, TECX will show a very negative growth in Earnings Per Share. The EPS will decrease by -11.88% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-117.96%
EPS Next 2Y-17.51%
EPS Next 3Y-11.88%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TECX Yearly Revenue VS EstimatesTECX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
TECX Yearly EPS VS EstimatesTECX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TECX. In the last year negative earnings were reported.
Also next year TECX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TECX Price Earnings VS Forward Price EarningsTECX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TECX Per share dataTECX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

TECX's earnings are expected to decrease with -11.88% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.51%
EPS Next 3Y-11.88%

More info and screens

0

5. Dividend

5.1 Amount

TECX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TECTONIC THERAPEUTIC INC

NASDAQ:TECX (1/30/2025, 7:05:28 PM)

After market: 54.01 -0.83 (-1.51%)

54.84

+29.12 (+113.22%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners43.68%
Inst Owner Change0.18%
Ins Owners26.47%
Ins Owner Change31.7%
Market Cap808.89M
Analysts84
Price Target76.16 (38.88%)
Short Float %6.63%
Short Ratio4.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-113.13%
Min EPS beat(2)-183.66%
Max EPS beat(2)-42.6%
EPS beat(4)2
Avg EPS beat(4)-31.34%
Min EPS beat(4)-183.66%
Max EPS beat(4)59.15%
EPS beat(8)2
Avg EPS beat(8)-72.36%
EPS beat(12)4
Avg EPS beat(12)-48.32%
EPS beat(16)7
Avg EPS beat(16)-34.22%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.34%
PT rev (3m)24.44%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-948.08%
EPS NY rev (1m)0%
EPS NY rev (3m)-64.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.38
P/tB 5.38
EV/EBITDA N/A
EPS(TTM)-9.74
EYN/A
EPS(NY)-5.22
Fwd EYN/A
FCF(TTM)-3.42
FCFYN/A
OCF(TTM)-3.41
OCFYN/A
SpS0
BVpS10.19
TBVpS10.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.24%
ROE -36.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.43%
ROA(5y)N/A
ROE(3y)-65.98%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.39
Quick Ratio 9.39
Altman-Z 11.25
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)65.25%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-399.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-172.73%
EPS Next Y-117.96%
EPS Next 2Y-17.51%
EPS Next 3Y-11.88%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y32.03%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-8.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y35.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35%
OCF growth 3YN/A
OCF growth 5YN/A